{"id":3256,"date":"2008-07-11T22:16:59","date_gmt":"2008-07-12T02:16:59","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=3256"},"modified":"2008-07-11T22:16:59","modified_gmt":"2008-07-12T02:16:59","slug":"respuesta-al-caso-escolar-con-verrugas-vulgares-periungueales-presentado-en-la-edicion-202","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/3256","title":{"rendered":"Respuesta al caso Escolar con verrugas vulgares periungueales presentado en la edici\u00f3n 202"},"content":{"rendered":"<p><strong>Primer reto:<\/strong><\/p>\n<p><strong>Escolar con verrugas vulgares periungueales. Autores: Faddy Graterol, Nayrin S\u00fanico, Zulay Rivera, V\u00edctor Che Le\u00f3n, Carmen Kannee. &nbsp;Instituto Biomedicina. Caracas<\/strong><\/p>\n<p><strong>Utilizamos inmunoterapia con DNCB:<\/strong><\/p>\n<p><!--more--> <a href=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/2008\/06\/202\/verrugas.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-3257\" src=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/2008\/06\/202\/verrugas-300x225.jpg\" title=\"verrugas\" width=\"300\" height=\"225\" srcset=\"https:\/\/piel-l.org\/blog\/wp-content\/uploads\/2008\/06\/202\/verrugas-300x225.jpg 300w, https:\/\/piel-l.org\/blog\/wp-content\/uploads\/2008\/06\/202\/verrugas.jpg 1062w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p><strong>Revision de la inmunoterapia en verrugas vulgares:<\/strong><\/p>\n<ul>\n<li>La inducci\u00f3n de hipersensibilidad retardada, se usa en tto de verrugas<\/li>\n<li>Difenciprona (DPCP), dinitroclorobenceno (DNCB) y dibutilester del \u00e1cido escu\u00e1rico (SADBE), utilizados con buenos resultados (60-88%)<\/li>\n<li>Sensibilizaci\u00f3n variable: desde ausencia (1-3%) hasta eczema general<\/li>\n<li>DNCB: mutag\u00e9nico seg\u00fan test de Ames y genot\u00f3xico por cambios en la cromatina hermana de los fibroblastos de piel humana<\/li>\n<li>En la pr\u00e1ctica no existe evidencia de carcinogenicidad<\/li>\n<li>SADBE y DPCP no son mutag\u00e9nicos seg\u00fan el test de Ames<\/li>\n<li>SADBE mayor costo<\/li>\n<li>Sensibilizaci\u00f3n con DNCB 2% en verruga, oclusi\u00f3n por 48 horas. Repetir cada 1-4 semanas hasta que desaparezcan<\/li>\n<\/ul>\n<p><em>Sterling J, .Handfield, Hudson P. Guidelines for&#8230; cutaneous warts .Br J Dermatol 2001;144:4-11<\/em><\/p>\n<p><em>Goihman M, Fern\u00e1ndez J, Convit J. Inmunoterapia verrugas vulgares con DNCB.Med Cut I L A 1976;4:187-94<\/em><\/p>\n<p><em>Buckley D, et al. &#8230;use of topical contact sensitizers in benign dermatoses.Br J Dermatol 2001;145:385-405<\/em><\/p>\n<p><em>&nbsp;<\/em><\/p>\n<p><strong>Interesante observacion<\/strong><\/p>\n<ul>\n<li>Imiquimod y DNCB pueden ser complementarios<\/li>\n<li>DNCB act\u00faa creando un nuevo ant\u00edgeno y el imiquimod favorecer\u00eda la respuesta inmune para el ant\u00edgeno compuesto<\/li>\n<li>Pacientes que no responden a DNCB<\/li>\n<li>Al asociar Imiquimod capacidad de respuesta al DNCB<\/li>\n<li>Pacientes que no responden al imiquimod<\/li>\n<li>Al asociar DNCB, nuevo Ag combinado reconocido x sistema inmunitario estimulado por imiquimod<\/li>\n<\/ul>\n<p><em>Goihman M. Combined Inmunotherapy of recalcitrant warts. Int J Dermatol 2006;45:627-31<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Primer reto: Escolar con verrugas vulgares periungueales. Autores: Faddy Graterol, Nayrin S\u00fanico, Zulay Rivera, V\u00edctor Che Le\u00f3n, Carmen Kannee. &nbsp;Instituto Biomedicina. Caracas Utilizamos inmunoterapia con DNCB:<\/p>\n","protected":false},"author":43,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132],"tags":[],"class_list":["post-3256","post","type-post","status-publish","format-standard","","category-como-trataria-usted"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/3256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=3256"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/3256\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=3256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=3256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=3256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}